{"id":"nai-nivolumab-ipilimumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:27:43.630571","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NAI (a natural killer cell activator) primes innate immune responses, while Nivolumab and Ipilimumab are checkpoint inhibitors that remove brakes on T-cell and immune activation. Together, they work synergistically to enhance both innate and adaptive anti-tumor immunity through complementary mechanisms of immune checkpoint blockade and NK cell activation.","oneSentence":"This triple combination enhances anti-tumor immunity by activating natural killer cells (NAI), blocking PD-1 checkpoint inhibition (Nivolumab), and blocking CTLA-4 checkpoint inhibition (Ipilimumab).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:35.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Advanced renal cell carcinoma"},{"name":"Other solid tumors (Phase 3 evaluation)"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NAI + Nivolumab + Ipilimumab","genericName":"NAI + Nivolumab + Ipilimumab","companyName":"ImmunityBio, Inc.","companyId":"immunitybio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple combination enhances anti-tumor immunity by activating natural killer cells (NAI), blocking PD-1 checkpoint inhibition (Nivolumab), and blocking CTLA-4 checkpoint inhibition (Ipilimumab). Used for Metastatic melanoma, Advanced renal cell carcinoma, Other solid tumors (Phase 3 evaluation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}